Fig. 1: TIGIT-expressing CD4+ T cell subsets correlate disease activity in patients with systemic autoimmune diseases. | Communications Biology

Fig. 1: TIGIT-expressing CD4+ T cell subsets correlate disease activity in patients with systemic autoimmune diseases.

From: Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells

Fig. 1

PBMCs from ten untreated RA patients, ten exacerbated SLE patients, ten untreated SjS patients, and 15 HCs were immunophenotyped. The proportions of TIGIT (a) and PD-1 (b) at each developmental stage (Tn, Tcm, Tem, Tfh, Tph, non-Tfh/Tph) among CD4+ T cells from the HCs (blue) and the patients with RA (red), SLE (green), and SjS (purple) are shown. The proportions of TIGIT (c) and PD-1 (d) at each developmental stage (Tn, Tcm, Tem, Temra) among CD8+ T cells from the HCs (blue) and the patients with RA (red), SLE (green) and SjS (purple) are shown. Error bars represent the mean ± SEM, and P values were determined by the Wilcoxon rank sum test. *P < 0.05, **P < 0.01, ***P < 0.001. A heatmap indicating the correlations between the proportions of TIGIT− (e) or PD-1- (f) expressing cells and disease activity (RA: DAS-28CRP, SLE: SLEDAI, SjS: ESSDAI) is shown. The numbers indicate the correlation coefficients in of Spearman’s test. *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page